AIM: The aim of the study was to assess the state of the art of the use of bone-seeking radiopharmaceuticals for palliation therapy of pain from bone metastases. METHODS: A systematic literature search was conducted about therapy with 89Sr-chloride and 153Sm-EDTMP between 2001-2011. The primary outcomes were efficacy and toxicity. Descriptive and quantitative data were extracted from each study, calculating event rates and odds ratio (OR) with 95% confidence intervals (CI) for pooled analysis. Subgroup analyses were performed. RESULTS: Fifty-seven studies contributed to the systematic review. Forty-six studies used radiopharmaceuticals as a single agent, 15 investigated therapeutic combinations. Most of the studies included patients with prostate cancer. The overall efficacy of bone-seeking radiopharmaceuticals as single agents was 70%, whereas it was 74% when used in combination with other therapies. Complete response was reported in 27% of patients. Efficacy resulted to be 70% for prostate cancer and 79% for breast cancer. The overall toxicity of radiopharmaceuticals was 15%: the toxicity was 11% selecting only studies reporting on the use of radiopharmaceuticals as a single agent. No significant difference was found between bone-seeking radiopharmaceuticals and other oncological treatments regarding efficacy or toxicity. Reports of objective response outcomes suggest that bone-seeking radiopharmaceuticals have some cytotoxic activity, either alone or combination with chemotherapy. CONCLUSION: This literature analysis emphasizes multiple evidences of high efficacy and low toxicity of bone seeking radiopharmaceuticals; moreover, this therapy may have a therapeutic potential beyond simple palliation of bone pain.
AIM: The aim of the study was to assess the state of the art of the use of bone-seeking radiopharmaceuticals for palliation therapy of pain from bone metastases. METHODS: A systematic literature search was conducted about therapy with 89Sr-chloride and 153Sm-EDTMP between 2001-2011. The primary outcomes were efficacy and toxicity. Descriptive and quantitative data were extracted from each study, calculating event rates and odds ratio (OR) with 95% confidence intervals (CI) for pooled analysis. Subgroup analyses were performed. RESULTS: Fifty-seven studies contributed to the systematic review. Forty-six studies used radiopharmaceuticals as a single agent, 15 investigated therapeutic combinations. Most of the studies included patients with prostate cancer. The overall efficacy of bone-seeking radiopharmaceuticals as single agents was 70%, whereas it was 74% when used in combination with other therapies. Complete response was reported in 27% of patients. Efficacy resulted to be 70% for prostate cancer and 79% for breast cancer. The overall toxicity of radiopharmaceuticals was 15%: the toxicity was 11% selecting only studies reporting on the use of radiopharmaceuticals as a single agent. No significant difference was found between bone-seeking radiopharmaceuticals and other oncological treatments regarding efficacy or toxicity. Reports of objective response outcomes suggest that bone-seeking radiopharmaceuticals have some cytotoxic activity, either alone or combination with chemotherapy. CONCLUSION: This literature analysis emphasizes multiple evidences of high efficacy and low toxicity of bone seeking radiopharmaceuticals; moreover, this therapy may have a therapeutic potential beyond simple palliation of bone pain.
Authors: Joyce M van Dodewaard-de Jong; John M H de Klerk; Haiko J Bloemendal; Daniela E Oprea-Lager; Otto S Hoekstra; H Pieter van den Berg; Maartje Los; Aart Beeker; Marianne A Jonker; Joe M O'Sullivan; Henk M W Verheul; Alfons J M van den Eertwegh Journal: Eur J Nucl Med Mol Imaging Date: 2017-04-18 Impact factor: 9.236
Authors: H Shibata; S Kato; I Sekine; K Abe; N Araki; H Iguchi; T Izumi; Y Inaba; I Osaka; S Kato; A Kawai; S Kinuya; M Kodaira; E Kobayashi; T Kobayashi; J Sato; N Shinohara; S Takahashi; Y Takamatsu; K Takayama; K Takayama; U Tateishi; H Nagakura; M Hosaka; H Morioka; T Moriya; T Yuasa; T Yurikusa; K Yomiya; M Yoshida Journal: ESMO Open Date: 2016-03-16
Authors: Daria Handkiewicz-Junak; Thorsten D Poeppel; Lisa Bodei; Cumali Aktolun; Samer Ezziddin; Francesco Giammarile; Roberto C Delgado-Bolton; Michael Gabriel Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-16 Impact factor: 9.236